DBV Technologies S.A. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; comparisons are with the year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. Financial amounts below are in U.S. dollars unless stated otherwise.
Business context
DBV is a clinical-stage biopharmaceutical company developing Viaskin, a skin-patch platform for epicutaneous immunotherapy. It had no approved products and generated no product sales in either year. Its lead candidate, Viaskin Peanut, is being developed for peanut allergy; Viaskin Milk and the MAG1C diagnostic program are earlier-stage programs.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Product sales | $0 | $0 |
| Operating income, principally research tax credits and collaboration accounting | $4.8 million | $5.7 million |
| Research and development expense | $75.5 million | $70.3 million |
| Sales and marketing expense | $1.6 million | $4.4 million |
| General and administrative expense | $24.3 million | $30.5 million |
| Operating loss | $96.6 million | $98.6 million |
| Net loss | $96.3 million | $97.8 million |
| Basic and diluted net loss per share | $1.24 | $1.78 |
| Cash and cash equivalents at year-end | $209.2 million | $77.3 million |
| Net cash used in operating activities | $55.7 million | $108.2 million |
- Net losses continued, as expected for a company without product revenue. Conventional profit margins are not meaningful.
- Cash increased primarily from 2022 equity financing: approximately $194.1 million of net financing cash flow, including the $194 million PIPE and ATM sales. Operating cash use fell year over year; management attributes this in part to research-tax-credit reimbursements and cost reductions.
- Management expected year-end cash to fund operations for at least 12 months, while stating that additional capital would be needed to support development and any potential launch.
- Total assets were $246.5 million and total liabilities were $52.1 million at year-end. The company reported no bank loans or long-term financial debt. Lease liabilities were $3.0 million; conditional advances were fully repaid in 2022.
- Year-end equity was $194.5 million. Ordinary shares outstanding rose to 94.1 million from 55.1 million; 28.3 million pre-funded warrants remained outstanding, subject to ownership limits. These securities and any further fundraising may dilute shareholders.
Material changes and developments
- Net loss narrowed modestly, while R&D expense rose 7% to $75.5 million, primarily reflecting clinical costs and startup fees for the modified-patch VITESSE study. Sales and marketing and G&A expenses declined with restructuring and cost controls.
- In June 2022, the Phase 3 EPITOPE trial in children ages 1–3 met its primary endpoint: 67.0% of active-treatment subjects responded versus 33.5% on placebo (p<0.001). The filing reports more application-site reactions and four treatment-related or possibly related anaphylactic reactions in the active arm; eight subjects discontinued due to adverse events.
- The FDA lifted its partial clinical hold on VITESSE in December 2022 after protocol revisions. The study tests a modified Viaskin Peanut patch in children ages 4–7. At filing, management expected screening to begin in Q1 2023 and topline results in the first half of 2025.
- The company withdrew its EU marketing application for Viaskin Peanut in December 2021 after the EMA raised a major objection about the evidence from a single pivotal trial. It intended to resubmit when a second pivotal data set became available.
- The PEOPLE open-label extension reported long-term desensitization results after 36 months; these findings were from an open-label study and should be considered in that context.
Outlook, risks and unusual items
- Management expects continued operating losses and substantial R&D spending. Approval and commercialization of Viaskin Peanut remain uncertain; the company had no commercial-ready sales infrastructure.
- Key risks include clinical-trial outcomes and safety, FDA requirements concerning patch adhesion and efficacy, regulatory timing, reliance on single suppliers and contract manufacturers, and the need for additional financing. Market acceptance, reimbursement, competition and potential dilution are also material uncertainties.
- COVID-19-related enrollment challenges affected clinical programs, including the Nestlé MAG1C Phase 2 study. Management updated its completion-cost estimates; the balance sheet included a $19.8 million provision for loss at completion on the collaboration, and the auditor identified this estimate as a critical audit matter.
- The French research tax credit supported cash resources: $26.1 million of 2019–2021 credits was reimbursed in 2022. The 2022 research tax credit recognized as operating income was $5.7 million.
- The 2022 financing substantially increased cash and share count. The company also reported an operating-lease termination fee and related income for the Summit, New Jersey facility. Management stated disclosure controls and internal control over financial reporting were effective at year-end; the auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether VITESSE started on the expected timetable, its enrollment and safety/adhesion findings, and whether its results support a U.S. BLA submission.
- The regulatory strategy and evidence needed for Viaskin Peanut in toddlers and for a future EU resubmission, including the relevance of EPITOPE and the second pivotal study.
- Cash burn, financing needs and runway as clinical spending changes; verify the effect of future equity issuance and exercise of the 28.3 million pre-funded warrants.
- The Nestlé collaboration’s remaining study costs, milestone prospects and loss-at-completion estimate. The filing gives differing CRO-trial cost totals in different sections ($126.1 million and $161.6 million); reconcile these with the stated $48.7 million of non-cancellable CRO commitments.
- Clinical and manufacturing concentration risks, including dependence on Sanofi for active ingredients and FAREVA for Viaskin Peanut patches.